

1   **TITLE**

2   *Dolutegravir-related hyperglycemia among children and adolescents <18 years in Northern and*  
3                                   *Eastern Uganda: A cross-sectional study*

4  
5   **Authors:** Fridah Akello<sup>1\*</sup>, Damalie Nalwanga<sup>1,3</sup> Victor Musiime<sup>1,2</sup>, Sarah Kiguli<sup>1</sup>  
6   **Institutions:**

7   1. Department of Paediatrics and Child Health, School of Medicine, College of Health Sciences,  
8   Makerere University, P.O.Box, 7072, Kampala, Uganda.

9   2. Joint Clinical Research Center, Kampala, Uganda

10   3. Makerere Lung Institute, Kampala, Uganda

11   \* Corresponding author **email address:** [fridah.akello@gmail.com](mailto:fridah.akello@gmail.com)

12

13

14

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

## ABSTRACT

**Background:** The World Health Organization (WHO) recommended Dolutegravir (DTG) as the preferred anchor drug for first and second line Anti-Retroviral Treatment (ART) regimen. Case reports and studies have demonstrated new onset hyperglycemia among adults initiated or transitioned to DTG. There is paucity of data on DTG-related hyperglycemia among children and adolescents and subsequently, glycemc screening is not routinely conducted for those using DTG. We determined the prevalence and factors associated with DTG-related hyperglycemia in this age category.

**Methods:** This cross-sectional study was conducted from 28<sup>th</sup> October 2022 to 11<sup>th</sup> September 2023 at Soroti and Lira Regional Referral Hospitals. 251 children and adolescents under 18 years, on a DTG based ART regimen, were consecutively enrolled and data analyzed for 240 participants. Socio-demographic, anthropometric measurements, clinical, and laboratory variables were collected using a questionnaire. Random blood glucose testing, urine dipstick and HbA1c analyses were conducted. Data was entered into epiData version 4.6, cleaned, and analyzed using STATA version 17.0. Logistic regression was used to determine the relationship between outcome and predictor variables. A p-value < 0.05 was considered statistically significant at multivariate analysis.

**Results:** Of the 240 study participants, 55.4 % (n=133) were female and 71.7 % (n =172) were over 10 years. The prevalence of DTG-related-hyperglycemia was 20% (n=49) and 95.9% (n=47) met the criteria for pre-diabetes. Health education talks on Adverse events related to Dolutegravir was protective for hyperglycemia (**aOR 0.4, 95% CI 0.2-0.9**), **p = 0.035**.

**Conclusion:** The prevalence of DTG-related-hyperglycemia was high, occurring in every 2 in 10 children and adolescents. Health education talks on adverse events associated with DTG use

38 were found to be protective against hyperglycemia. Routine glyceimic screening and monitoring  
39 therefore should be emphasized. Additionally, a strategy for health education talks focusing on  
40 lifestyle modifications to reduce the occurrence of hyperglycemia should be developed.

41 **Key words:** Hyperglycemia, Dolutegravir

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

## 61 **Introduction**

62 The world Health Organization and Ministry of Health recommended Dolutegravir (DTG), an  
63 Integrase Strand Transfer Inhibitor (INSTI) as the preferred anchor drug for first and second line  
64 HIV treatment options (1). This was supported by study results from the ODYSSEY (Once-daily  
65 Dolutegravir based ART in Young people versus Standard Therapy) and Penta-17 trials that  
66 showed Dolutegravir to be superior to the current standard of care ART regimen (predominantly  
67 a Protease Inhibitor based-ART) in children and adolescents (2).

68 Subsequently, all eligible persons living with HIV are being initiated or optimized to a DTG  
69 containing regimen however, a number of case reports and studies among adult patients  
70 document symptomatic hyperglycemia associated with initiation on DTG (3–5). Hyperglycemia  
71 is defined as a fasting blood glucose level of  $>7.0$  mmol/L or a random plasma glucose greater  
72 than 11.1 mmol/L and or an HBA1C level  $>6.5\%$ (6). The prediabetes state defined by the  
73 American Diabetic association as a state of intermediate hyperglycemia based on blood glucose  
74 levels or estimates of glycated haemoglobin levels is also considered hyperglycemia.

75 DTG is postulated to cause hyperglycemia through chelation of magnesium to prevent HIV from  
76 integrating into host DNA(7,8). Because magnesium serves as a cofactor in post-receptor insulin  
77 action, Magnesium chelation may cause disorders of glucose metabolism (9,10). In addition,  
78 concomitant HIV infection is associated with insulin resistance resulting from immune activation  
79 and chronic inflammation thus worsening the hyperglycemia (11).

80 Despite these isolated study findings, there is paucity of data on DTG associated hyperglycemia  
81 and even more particularly in the pediatric and adolescent population. Hyperglycemia if  
82 undetected or managed late poses severe acute complications including Diabetic Ketoacidosis

83 (DKA) and Hyperosmolar Hyperglycemic State (HHS) (12). Chronic complications are related  
84 to the micro vascular changes which predispose to retinopathy, nephropathy and neuropathy  
85 resulting from cellular damage inflicted by the hyperglycemia (13).  
86 Ministry of Health (MoH) Uganda HIV treatment guidelines (2022) recommend routine  
87 monitoring for therapeutic response and drug related adverse events for all children and  
88 adolescents on ART however glycemic monitoring is not specifically mentioned. In contrast  
89 however, baseline random blood sugar testing and routine monitoring for adults over 45 years is  
90 emphasized in these treatment guidelines. (14). Furthermore, there is scanty data on prevalence  
91 and factors associated with DTG-related-hyperglycemia among children and adolescents in  
92 Uganda and this study addressed this knowledge gap. Findings from this study form a point of  
93 reference for additional studies and guidelines to improve adverse events monitoring for children  
94 and adolescents on DTG.

## 95 **Methods**

### 96 **Study site**

97 This was conducted at the HIV clinics of Soroti and Lira Regional Referral Hospitals (RRHs)  
98 both tertiary level health care facilities in Eastern and Northern Uganda respectively. Soroti RRH  
99 was the primary study site and Lira RRH was included as an additional site having reached  
100 saturation in Soroti. Lira RRH was chosen owing to its homogeneity to Soroti in regard to  
101 dietary and activity characteristics of the population. Both regions were ravaged by the 5 year  
102 LRA war in 2002-2006 and resultantly bore the brunt of the HIV epidemic with relatively high  
103 rates of HIV transmission. Each of the hospitals has one of the largest pediatric HIV enrollments  
104 in the respective regions and subsequently, a high number of children and adolescents on a DTG  
105 based ART regimen. Soroti RRH serves a catchment area with a population of 2.7 million

106 persons. Lira RRH on the other hand offers general and specialized health care services to a  
107 population of close to 2.3 million individuals from the 9 districts of Lango sub-region.

### 108 **Study population and sample size determination**

109 These were all children and adolescents below 18 years on a DTG containing regimen for at least  
110 6 months attending the paediatric HIV clinics of Soroti and Lira RRHs. The study was conducted  
111 from 28<sup>th</sup> October 2022 to 11<sup>th</sup> September 2023. The sample size of 240 was determined using  
112 the Kish Leslie and Fleiss formulae.

### 113 **Study design and data collection procedure**

114 The study used a cross sectional study design. Quantitative data was collected using a  
115 questionnaire onto which socio-demographic information, anthropometry and relevant history  
116 were captured.

### 117 **Inclusion and exclusion criteria**

118 We included all participants below 18 years, on a DTG based regimen for at least 6 months with  
119 documented good adherence in the last 4 months and excluded those who had an acute illness, a  
120 past history of hyperglycemia or if they declined to consent or assent.

### 121 **Study variables**

122 The dependent variable was hyperglycemia defined as a random plasma glucose concentration of  
123  $\geq 11.1$  mmol/l (200 mg/dl) or an HbA1c of  $> 6.5\%$  (15). Patients with prediabetic glycemie  
124 levels were also considered to have hyperglycemia. This was determined by a random plasma  
125 glucose of 7.8-11.0 mmol/L or an HBA1C of 5.7-6.4%.

126 Independent variables included patient factors like age, sex, current and pretreatment Body Mass  
127 Index (BMI) for age z scores, Pre-existing comorbidities, Age at diagnosis of HIV, Age at ART  
128 initiation, Use of other medications, WHO Stage, Duration on ART, Duration on DTG and most

129 recent viral load. Health system factors included Glycemic screening, patient Education on DTG  
130 Adverse Events and Glycemic Monitoring

### 131 **Data management and analysis**

132 Data was entered into EpiData (v4.6) and exported to STATA version 17 for analysis. Univariate  
133 analysis was done for socio-demographic and baseline clinical characteristics and was presented  
134 in form of frequencies, proportions and means. A bivariate analysis was performed to determine  
135 the association between the dependent and independent variables. Variables with p values <0.2  
136 were considered for multivariate analysis. A logistic regression was then performed to determine  
137 the statistical significance of the association between these variables and hyperglycemia. Factors  
138 with P values <0.05 were considered statistically significant.

### 139 **Ethical consideration**

140 The study protocol was approved by the School of Medicine Research and Ethics Committee  
141 (SOMREC), reference number Mak-SOMREC-2022-405. Administrative clearance was further  
142 obtained from the hospital directors and research committees of Soroti and Lira RRHs. Parental  
143 consent was obtained for participants below 8 years while assent was obtained for participants 8  
144 years and above and substantiated by a witness within the clinic. All consent was written and  
145 documented on a parental consent or assent form as applicable.

### 146 **Results**

#### 147 **Participant Demographic and baseline clinical characteristics**

148 Data was analyzed for 240 participants. Mean age was 12.36 ±3.76 years. Females accounted for  
149 55.4% (n=133) and 71.7% (n=172) were over 10 years of age. Median age at HIV diagnosis was  
150 24.06 (IQR, 1.33-46.79) months. Majority of participants, 202 (84.2%), had been on ART for more

151 than 5 years, only 37.9% (n=91) had been on a DTG-containing regimen for more than 2 years  
 152 while 68.8% (n=165) initiated ART before the age of five years s presented in **Table 1** below.

153 **Table 1: Demographic and baseline clinical characteristics of study participants**

| Variable                                      | Total n=240 | Percentage (%) |
|---|-------------|----------------|
| <b>Age (Years)</b>                            |             |                |
| 1-4   | 10          | 4.2            |
| 5-10  | 58          | 24.2           |
| >10   | 172         | 71.7           |
| <b>Sex</b>                                    |             |                |
| Female  | 133         | 55.4           |
| Male  | 107         | 44.6           |
| <b>Age at ART STAT (Years)</b>                |             |                |
| 0-4   | 165         | 68.8           |
| 5-10  | 62          | 25.8           |
| >10   | 13          | 5.4            |
| <b>Duration on ART(Years)</b>                 |             |                |
| <1  | 4           | 1.7            |
| 1-5   | 34          | 14.2           |
| >5  | 202         | 84.2           |
| <b>Duration on DTG</b>                        |             |                |
| <1  | 26          | 10.8           |
| 1-2   | 123         | 51.3           |
| >2  | 91          | 37.9           |
| <b>Baseline CD4</b>                           |             |                |
| <100 cells/mm <sup>3</sup>                    | 6           | 2.5            |
| 100 <250 cells/mm <sup>3</sup>                | 8           | 3.3            |
| 250-500 cells/ mm <sup>3</sup>                | 16          | 6.7            |
| >500 cells/ mm <sup>3</sup>                   | 37          | 15.4           |
| Unknown                                       | 173         | 72.1           |
| <b>Baseline ART</b>                           |             |                |
| NVP based                                     | 128         | 53.3           |
| EFV based                                     | 60          | 25.0           |
| PI based                                      | 40          | 16.7           |
| DTG   | 12          | 5.0            |
| <b>WHO Stage at ART initiation</b>            |             |                |
| Stage I                                       | 177         | 73.8           |
| Stage II                                      | 29          | 12.1           |
| Stage III                                     | 26          | 10.8           |
| Stage IV                                      | 8           | 3.3            |
| <b>BMI for age z scores at DTG initiation</b> |             |                |
| Normal  | 197         | 82.1           |
| Overweight                                    | 10          | 4.2            |
| Underweight                                   | 11          | 4.6            |
| Not assessed                                  | 22          | 9.1            |

*Abbreviations: NVP Nevirapine EFV Efavirenz PI Protease Inhibitor*



154 Only 37.9% (n=67) had results for baseline CD4 counts, of which 5.8% (n=14) had a CD4 count  
155 below 250 cells/mm<sup>3</sup>. Approximately 53.3% (n=128) of the study participants initially received  
156 Nevirapine as baseline ART, and only 5.0% (n=12) were initiated on a DTG-based regimen.  
157 Significantly, 73.8% (n=177) of the participants were classified as WHO stage I at the initiation  
158 of ART, however, upon the most recent WHO clinical staging, this percentage notably increased  
159 to 94.6%, highlighting substantial clinical improvement in the study population.

### 160 **Recent clinical characteristics of study participants**

161 Majority of clients, 92.1% (n=221), were still on a first-line ART regimen. Specifically, 62.9%  
162 (n=151) of participants are on a Tenofovir-based ART drug combination as in *Table 2* below.

163 *Table 2: Recent clinical characteristics of study participants*

| Variable                            | Total n=240 | Percentage (%) |
|-------------------------------------|-------------|----------------|
| <b>Current regimen line</b>         |             |                |
| 1st Line                            | 221         | 92.1           |
| 2nd Line                            | 17          | 7.1            |
| 3rd Line                            | 2           | 0.8            |
| <b>Current ART Regimen</b>          |             |                |
| ABC based                           | 80          | 33.3           |
| TDF Based                           | 151         | 62.9           |
| AZT Based                           | 8           | 3.3            |
| PI and NRTI based                   | 1           | 0.4            |
| <b>Viral Load</b>                   |             |                |
| Suppressed                          | 199         | 82.9           |
| Non suppressed                      | 38          | 15.8           |
| Not done                            | 3           | 1.3            |
| <b>Current BMI for age z scores</b> |             |                |
| Normal                              | 205         | 85.4           |
| Overweight                          | 12          | 5.0            |
| Underweight                         | 23          | 9.6            |
| <b>Recent WHO stage</b>             |             |                |
| Stage I                             | 227         | 94.6           |
| Stage II                            | 10          | 4.2            |
| Stage III                           | 2           | 0.8            |
| Stage IV                            | 1           | 0.4            |

164

165 Only 2 (0.9%) participants, have transitioned to a third-line ART regimen. It is noteworthy that  
166 only 82.9% of the participants had achieved virological suppression, defined as having a viral load  
167 less than 1000 copies/ml.

168 Additionally, 85.4% (n=205) of the participants had normal body mass index (BMI) for age z-  
169 scores and there were notably no significant changes in BMI for age z-scores between the  
170 initiation of DTG and recent measurements.

### 171 **Prevalence of Dolutegravir-related-hyperglycemia**

172 A participant was considered to have hyperglycemia if either their RBS measurement was  
173 greater than 7.8 mmol/L or their HbA1c level was equal to or greater than 5.7%. This inclusive  
174 definition also encompassed the prediabetes state.

175 Overall, the findings revealed that 49 (20%) [95% CI 0.1506, 0.2578] study participants had  
176 hyperglycemia. Notably, HbA1C levels varied from 3.5% - 6.7%.

177 Among those diagnosed with hyperglycemia, HbA1c alone was responsible for identifying  
178 hyperglycemia in the majority, with 46 (93.9%) participants diagnosed using this measure.

179 Conversely, only a small proportion, 3 (6.1%), were identified as hyperglycemic based on the  
180 RBS measurement alone. Only two participants had diabetic range HbA1C levels.

### 181 **Patient factors associated with DTG-related-hyperglycemia**

182 At bivariate analysis for the clinical characteristics of study participants, age, duration on DTG  
183 and baseline CD4 had P values <0.2 and were considered for the multivariate analysis as shown  
184 in **Table 3** below.

185 *Table 3: Patient factors associated with DTG-related-hyperglycemia*

| Variable                                | Hyperglycemia     |                   | Crude OR (95% CI) | P Value |
|---|-------------------|-------------------|-------------------|---------|
|   | No<br>n=191 (80%) | Yes<br>n=49 (20%) |                   |         |
| <b>Current regimen line</b>             |                   |                   |                   | 0.071*  |
| 1st Line                                | 172(77.8)         | 49(22.2)          | 1                 |         |
| 2nd Line                                | 17(100.0)         | 0(0.0)            | 0.1(0.01, 1.7)    | 0.110   |
| 3rd Line                                | 2(100.0)          | 0(0.0)            | 0.7(0.03, 14.8)   | 0.817   |
| <b>Current ART Regimen</b>              |                   |                   |                   | 0.172*  |
| ABC based                               | 70(87.5)          | 10(12.5)          | 1                 |         |
| TDF Based                               | 114(75.5)         | 37(24.5)          | 2.2(1.04, 4.6)    | 0.038*  |
| AZT Based                               | 6(75.0)           | 2(25.0)           | 2.6(0.5, 12.7)    | 0.244   |
| PI and NRTI based                       | 1(100.0)          | 0(0.0)            | 2.2(0.1, 58.6)    | 0.629   |
| <b>Viral Load</b>                       |                   |                   |                   | 0.308   |
| Suppressed                              | 155(77.9)         | 44(22.1)          | 1                 |         |
| Non suppressed                          | 33(86.8)          | 5(13.2)           | 0.6(0.2, 1.5)     | 0.257   |
| Not done                                | 3(100.0)          | 0(0.0)            | -                 |         |
| <b>Current BMI for age z scores</b>     |                   |                   |                   | 0.791   |
| Normal                                  | 165(80.5)         | 40(19.5)          | 1                 |         |
| Overweight                              | 8(66.7)           | 4(33.3)           | 2.2(0.7, 7.1)     | 0.205   |
| Underweight                             | 18(78.3)          | 5(21.7)           | 1.2(0.4, 3.3)     | 0.706   |
| Total                                   | 165(80.5)         | 40(19.5)          |                   |         |
| <b>Recent WHO stage</b>                 |                   |                   |                   | 0.854   |
| Stage I                                 | 180(79.3)         | 47(20.7)          | 1                 |         |
| Stage II                                | 8(80.0)           | 2(20.0)           | 1.1(0.3, 4.7)     | 0.880   |
| Stage IV                                | 2(100.0)          | 0(0.0)            | 0.8(0.04, 16.1)   | 0.860   |
| Not staged                              | 1(100.0)          | 0(0.0)            | 1.3(0.01, 31.6)   | 0.885   |
| <b>Herbal Remedies</b>                  |                   |                   |                   | 0.129*  |
| No                                      | 174(80.9)         | 41(19.1)          | 1                 |         |
| Yes                                     | 17(68.0)          | 8(32.0)           | 2.0(0.8, 5.0)     | 0.114   |
| <b>History suggesting hyperglycemia</b> |                   |                   |                   | 0.001*  |
| Polyuria                                | 3(100.0)          | 0(0.0)            | -                 |         |
| Polydipsia                              | 0(0.0)            | 3(100.0)          | -                 |         |
| Polyphagia                              | 0(0.0)            | 1(100.0)          | -                 |         |
| None                                    | 188(80.7)         | 45(19.3)          | -                 |         |
| <b>Family History of HTN</b>            |                   |                   |                   | 0.035*  |
| No                                      | 178(81.3)         | 41(18.7)          | 1                 |         |
| Yes                                     | 13(61.9)          | 8(38.1)           | 2.7(1.1, 6.8)     | 0.034   |

186 A subset of study participants, 25 (11.7%), reported a history of using herbal remedies and only  
 187 8 (32%) were found to have hyperglycemia. Majority of study participants 233 (97.1%) did not  
 188 have any history suggestive of hyperglycemia and only 21 (8.8%) had a family history of  
 189 hypertension.

190 At bivariate analysis, current regimen line, current ART regimen, history of use of herbal  
 191 remedies and family history of hypertension was considered for multivariate analysis.

192 **Health system factors associated with DTG-related-hyperglycemia**

193 According to the study data, only 45(18.8%) participants had a baseline random blood sugar  
 194 done at initiation of DTG while 169 (70.4%) had never received any form of glyceimic  
 195 monitoring. The majority of participants, 60.4% had not received a health education talk on DTG  
 196 related adverse events and only 54.6% were aware of reporting avenues for DTG related adverse  
 197 events. This is summarized in *Table 4* below.

198 **Table 4: Health System factors associated with DTG-related-hyperglycemia**

| Variable                                     | Hyperglycemia |                  |                   | Crude OR<br>(95% CI) | P value       |
|--|---------------|------------------|-------------------|----------------------|---------------|
|  | Total         | No<br>n=191(80%) | Yes<br>n=49 (20%) |                      |               |
| <b>Base line BGL at DTG Start</b>            |               |                  |                   |                      |               |
| Not done                                     | 195(81.3)     | 147(75.4)        | 48(24.6)          | 1                    | <b>0.008*</b> |
| Normal                                       | 44(18.3)      | 43(97.7)         | 1(2.3)            | 0.1(0.01, 0.6)       |               |
| Elevated                                     | 1(0.4)        | 1(100.0)         | 0(0.0)            | -                    |               |
| <b>BGL Monitoring on DTG</b>                 |               |                  |                   |                      |               |
| Never  | 169(70.4)     | 125(74.0)        | 44(26.0)          | 1                    | 0.033         |
| once   | 48(20.0)      | 43(89.6)         | 5(10.4)           | 0.4[0.1, 0.9]        |               |
| More than once                               | 23(9.6)       | 23(100.0)        | 0(0.0)            | 0.1[0.04, 1.01]      |               |
| <b>Health Education on DTG AEs</b>           |               |                  |                   |                      |               |
| No   | 145(60.4)     | 105(72.4)        | 40(27.6)          | 1                    | <b>0.001*</b> |
| Yes  | 95(39.6)      | 86(90.5)         | 9(9.5)            | 0.3[0.1, 0.6]        |               |
| <b>Awareness of DTG AE reporting avenues</b> |               |                  |                   |                      |               |
| No   | 109(45.4)     | 90(82.6)         | 19(17.4)          | 1                    | 0.305         |
| Yes  | 131(54.6)     | 101(77.1)        | 30(22.9)          | 0.3(0.1, 0.6)        |               |

*Abbreviations: BGL: Blood glucose level AE: Adverse events*

199 The bivariate analysis in this study showed that there were significant associations between  
 200 glyceimic monitoring and health education talks on DTG side effects with the occurrence of  
 201 hyperglycemia. Participants who had their plasma glucose levels monitored at least once had a  
 202 lower likelihood of developing hyperglycemia, (OR 0.4, 95% CI, 0.1-0.9) P = 0.033.

203 Similarly participants who had received a health education talk on the side effects of DTG had a  
 204 lower likelihood of developing hyperglycemia (OR 0.3, 95% CI, 0.1-0.6), P=0.001.

205 **Multivariate analysis of factors associated with DTG-related-hyperglycemia**

206 At multivariate analysis, only Health Education on Dolutegravir associated adverse events was  
 207 found to have a statistically significant association with developing DTG-related hyperglycemia  
 208 as summarized in *Table 5* below.

209 *Table 5: Multivariate analysis of factors associated with Dolutegravir-related-hyperglycemia*

| Variables                          | COR[95% conf. interval] | P-value      | AOR[95% conf. interval] | P-values     |
|------------------------------------|-------------------------|--------------|-------------------------|--------------|
| <b>Duration on DTG[Years]</b>      |                         |              |                         |              |
| <1                                 | 1                       |              | 1                       |              |
| 1-2                                | 2.4[0.7, 7.8]           | 0.158        | 2.1[0.6, 7.3]           | 0.234        |
| >2                                 | 1.3[0.4, 4.5]           | 0.707        | 1.2[0.3, 4.7]           | 0.748        |
| <b>Current ART Regimen</b>         |                         |              |                         |              |
| ABC based                          | 1                       |              | 1                       |              |
| TDF Based                          | 2.2[1.04, 4.6]          | 0.038        | 2.1[0.9, 4.6]           | 0.073        |
| AZT Based                          | 2.6[0.5, 12.7]          | 0.244        | 3.4[0.6, 18.7]          | 0.153        |
| PI and NRTI based                  | 2.2[0.1, 58.6]          | 0.629        | 5.6[0.2, 170.8]         | 0.326        |
| <b>Family History of HTN</b>       |                         |              |                         |              |
| No                                 | 1                       |              | 1                       |              |
| Yes                                | 2.7[1.1, 6.8]           | 0.034        | 1.6[0.6, 4.2]           | 0.358        |
| <b>BGL Monitoring on DTG</b>       |                         |              |                         |              |
| Never                              | 1                       |              | 1                       |              |
| once                               | 0.4[0.1, 0.9]           | 0.033        | 0.4[0.2, 1.2]           | 0.101        |
| More than once                     | 0.1[0.04, 1.01]         | 0.051        | 0.1[0.01, 1.7]          | 0.113        |
| <b>Health Education on DTG AEs</b> |                         |              |                         |              |
| No                                 | 1                       |              | 1                       |              |
| Yes                                | <b>0.3[0.1, 0.6]</b>    | <b>0.001</b> | <b>0.4[0.2, 0.9]</b>    | <b>0.035</b> |

210 **Abbreviations:** AEs, Adverse events HTN Hypertension ABC Abacavir TDF Tenofovir AZT Zidovudine PI

211 *Protease Inhibitor*

212 After adjusting for other factors, participants who had health education talks on DTG-related-  
 213 hyperglycemia were 60% less likely to develop hyperglycemia compared to those who did not  
 214 receive any (AOR 0.4, 95% CI, 0.2-0.9, P = 0.035).

## 215 **Discussion**

216 This cross-sectional study determined the prevalence and factors associated with Dolutegravir-  
217 related hyperglycemia among children and adolescents in two regional referral hospitals in  
218 Uganda. The study included a total of 240 participants from Soroti RRH and additional  
219 participants from Lira Regional Referral Hospital.

220 Hyperglycemic status was determined based on elevated random blood sugar or glycated  
221 hemoglobin levels. The study suggested an association between the use of a Dolutegravir-  
222 containing ART regimen and hyperglycemia.

223 The study findings reveal that among children and adolescents on a DTG-based ART regimen,  
224 the prevalence of hyperglycemia was 20%, indicating that approximately two out of every 10  
225 children were affected.

226 Furthermore, the prevalence of prediabetes and diabetic range hyperglycemia was 17.9% and  
227 2.1% respectively. This prevalence is higher compared to the estimated rates of prediabetes and  
228 diabetes in the broader African region, which is reported to be 8.6% and 3.3% respectively (16).  
229 The difference in prevalence could be attributed to the specific population studied (children and  
230 adolescents on DTG-based ART) who have an additional risk factor of HIV infection, which is  
231 known to be associated with an increased risk of hyperglycemia.

232 Results from a similar study conducted in Botswana by Moverman *et al.*; showed the prevalence  
233 of prediabetes and diabetic range hyperglycemia in the general population of persons living with  
234 HIV to be 30% and 6% respectively(17). The lower prevalence in our study can be explained by  
235 the fact that the former study was conducted in a population of older adults who were over 40  
236 years age and therefore had additional risk factors for hyperglycemia associated with older age.

237 It is important to highlight that there is currently no published data available on the prevalence of  
238 DTG-related hyperglycemia specifically in the child and adolescent age group. Abera *et al*; in  
239 2022 reported a prevalence of 14.7% among adult patients attending a tertiary hospital in  
240 Ethiopia. The higher prevalence in our study could be attributed to the inclusion of prediabetic  
241 HbA1C levels as part of the criteria for hyperglycemia in the current study, which was not  
242 considered in the Ethiopian study. This suggests that prediabetic states may contribute to the  
243 higher prevalence observed in the child and adolescent population.

244 In contrast, Odenyo *et al*; in 2020 reported a prevalence of 55.9% in their study conducted in an  
245 adult population in a Kenyan hospital(18). These findings may be attributed to the presence of  
246 additional risk factors in the adult age group like insulin resistance, impaired glucose tolerance,  
247 or age-related changes in metabolism that predisposes them to an increased risk of developing  
248 hyperglycemia.

249 Related studies include one by Bahamdain *et al*; in Arizona where 7% of adult study participants  
250 met the criteria for prediabetes 3-6 months after DTG initiation(19). However, in the current  
251 study, due to the cross-sectional study design, the survival time to developing prediabetes could  
252 not be determined. In addition, Namara *et al*; in their case control study in Uganda, reported that  
253 adults who had been previously exposed to a Dolutegravir-containing regimen had seven times  
254 higher odds of developing hyperglycemia compared to those with no history of exposure (20).

255 Dolutegravir has been postulated to cause hyperglycemia by a mechanism involving chelation of  
256 Magnesium which is critical for the action of viral integrase enzyme in the HIV replication cycle.  
257 These study findings should therefore be of great concern since current WHO and MoH-Uganda  
258 HIV care and treatment guidelines only emphasize DTG glycemic screening and monitoring for  
259 mainly adults over 45 years who are perceived to be at risk for hyperglycemia overlooking the

260 potential risk to children and adolescents which is probably based on an assumption that children  
261 and adolescents are usually euglycemic. These findings thus suggest that the prevalence of  
262 Dolutegravir-related hyperglycemia can vary across different populations and age groups.

263 At bivariate analysis, a number of factors were found to be associated with hyperglycemia and  
264 these included a history of using a TDF based ART regimen, family history of hypertension and  
265 history of health education on adverse events associated with DTG use.

266 Children and adolescents who received health education on the side effects of Dolutegravir were  
267 less likely to develop hyperglycemia cOR 0.3 ( $p = 0.001$ ). Furthermore, at multivariate analysis,  
268 after adjusting for other factors, health education talks remained significantly protective against  
269 DTG-related hyperglycemia, with (aOR) of 0.4 ( $p = 0.035$ ). This could be attributed to the fact  
270 that currently, facility based education sessions are also geared towards control of Non  
271 communicable Diseases (NCDs) with emphasis on enhancement of lifestyle modifications  
272 protective for diabetes and hypertension.

273 There has been a remarkable paradigm shift in the content of health education talks. Early at the  
274 start of the HIV epidemic, health education talks were focused on stigma reduction, adherence  
275 and disclosure however owing to the success of the ART program, PLHIV are living longer and  
276 faced with higher risk for NCDs given the additional risk posed by the HIV infection and the anti  
277 HIV drugs. The focus of health education sessions has had to include modalities for screening  
278 and prevention of NCDs.

279 Fitch *et al*; 2006 in their study demonstrated that weekly counseling by a dietician with main  
280 emphasis on healthy eating, rather than weight loss, was associated with a significant reduction  
281 in blood pressure, waist circumference and HbA1c (21). In addition, endurance and resistance



282 exercises have also been shown to have positive effects on metabolic parameters in HIV infected  
283 patients (22) therefore health education messages that highlight such lifestyle modifications are  
284 protective for hyperglycemia.

285 Other studies have shown that effective health education improves knowledge, attitude, and  
286 practices, particularly with regard to lifestyle modifications and dietary management,  
287 culminating into better glycemic control that can slow down the progression of diabetes and  
288 prevent downstream complications (23).

289 These findings thus highlight the importance of health education in reducing the risk of  
290 hyperglycemia in individuals using DTG.

291 The study did not reveal any statistically significant association between hyperglycemia and sex,  
292 BMI for age z scores, duration on Dolutegravir, WHO stage, baseline CD4 counts, and the use of  
293 herbal drug remedies. These findings differ from previous studies that have reported associations  
294 between these factors and Dolutegravir-related hyperglycemia. For example, Odenyo *et al*;  
295 found that females were 1.6 times more likely to develop DTG-related hyperglycemia (18),  
296 while Miiro *et al*; and Abera *et al*; reported that males were more likely to develop  
297 hyperglycemia (24,25). Additionally, Odenyo *et al*; found that overweight patients were 1.7  
298 times more likely to develop hyperglycemia. In terms of BMI for age z scores, the current study's  
299 findings align with studies by Namara *et al*; and the GLUMED study in Kampala, which also did  
300 not find a significant association between BMI and hyperglycemia (20,26). The duration on  
301 Dolutegravir also did not show a statistically significant association with hyperglycemia in  
302 contrast to the findings by Lamorde *et al*; in Uganda (5). Similarly, factors such as WHO stage,  
303 baseline CD4 counts, and the use of herbal drug remedies also did not demonstrate a significant  
304 association with hyperglycemia in the current study.

305 **Strength of the study**

306 This is among the few studies in Uganda to investigate the prevalence of DTG-related  
307 hyperglycemia among children and adolescents making this study valuable in addressing a  
308 critical knowledge gap that highlights the potential risk of hyperglycemia in younger age groups.  
309 Additionally, the inclusion of HbA1c as a diagnostic criterion for hyperglycemia adds to the  
310 robustness of the study since HbA1c is a reliable indicator of long-term glucose control and  
311 provides a comprehensive assessment of glycemetic status.

312 **Study limitations**

313 The study sites were hospitals based in peri-urban settings posing limitations in generalizability  
314 to other settings especially the urban rich who are predisposed to cofounders for hyperglycemia  
315 like obesity and sedentary lifestyles.

316 The cross-sectional study design limits ability to establish a causal relationship between  
317 hyperglycemia and DTG use. The absence of baseline plasma glucose measurements also  
318 hinders determination of the temporal relationship between hyperglycemia and DTG use.

319 The use of consecutive enrollment rather than random sampling and the limitation to participants  
320 attending the clinic on a specific day introduces selection bias, potentially affecting the  
321 representativeness of the sample.

322 Additionally, the study's sample size was not adequately powered, which may have influenced  
323 the study results. The sample size calculation based on prevalence estimates from the adult  
324 population may not accurately reflect the prevalence of hyperglycemia in children and

325 adolescents leading to an overestimation or underestimation of the required sample size,  
326 potentially affecting the precision and validity of the study findings.

327 The time period for the measurement of Random blood sugar after a meal was not standardized  
328 and therefore could have posted a falsely elevated plasma glucose level.

329 The study outcome which was hyperglycemia could have been over or under classified  
330 subsequently giving a relatively higher or lower prevalence respectively.

### 331 **Conclusions**

332 The prevalence of Dolutegravir-related-hyperglycemia is high occurring in every 2 in 10 children  
333 and adolescents. The findings highlight the need for increased attention to glycemic screening  
334 and monitoring in this population. Health education talks on DTG adverse events were found to  
335 be protective against hyperglycemia underscoring the need to develop comprehensive health  
336 education messages that address DTG related complications and ensure optimal care for children  
337 and adolescents on Dolutegravir-based ART regimens.

### 338 **Recommendations**

339 Based on the study findings, there should be advocacy for updates in HIV treatment guidelines to  
340 include specific recommendations for glycemic screening and monitoring for children and  
341 adolescents on Dolutegravir-based ART regimens.

342 The use of glycated hemoglobin (HbA1c) tests, for persons on a DTG based regimen should be  
343 supported given its accuracy in monitoring glycemic control over a longer duration.

344 Routine Glycemic screening and monitoring is recommended for children and adolescents on  
345 Dolutegravir-based ART regimens to support early detection and management of hyperglycemia.

346 Health Education programs for children, adolescents, and their caregivers should routinely focus  
347 on the potential side effects of Dolutegravir, including hyperglycemia with emphasis on the  
348 importance of lifestyle modifications, such as healthy eating habits and regular physical activity.  
349 To conduct longitudinal studies to investigate the long-term implications of Dolutegravir-related  
350 hyperglycemia in children and adolescents while evaluating the progression of hyperglycemia,  
351 its impact on metabolic health, and the effectiveness of different management strategies.

### 352 **Acknowledgements**

353 The authors would like to acknowledge the contribution of Ambrose Okibure for support in the  
354 statistical analysis and all the lecturers in the Department of Paediatrics and Child health,  
355 Makerere University for their insightful input from concept development to completion of the  
356 manuscript. We also appreciate Dr. Ben Watmon and Dr. Nathan Onyachi for providing  
357 clearance to conduct the study in Soroti and Lira RRHs.

358

359

360

361

362

363

364

365

## 366 **References**

- 367 1. The World Health Organisation. Statement on DTG - Geneva 18 May 2018. Who. 2018;
- 368 2. Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo CM, et al. ODYSSEY  
369 clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-  
370 based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to  
371 evaluate pragmatic WHO-weight-band based doluteg. BMC Infect Dis. 2021;
- 372 3. McLaughlin M, Walsh S, Galvin S. Dolutegravir-induced hyperglycaemia in a patient living with  
373 HIV. Journal of Antimicrobial Chemotherapy. 2018.
- 374 4. Kamal P, Sharma S. SUN-187 Dolutegravir Causing Diabetes. J Endocr Soc.  
375 2019;3(Supplement\_1).
- 376 5. Lamorde M, Atwiine M, Owarwo NC, Ddungu A, Laker EO, Mubiru F, et al. Dolutegravir-  
377 associated hyperglycaemia in patients with HIV. The Lancet HIV. 2020.
- 378 6. Tosur M, Viau-Colindres J, Astudillo M, Redondo MJ, Lyons SK. Medication-induced  
379 hyperglycemia: Pediatric perspective. BMJ Open Diabetes Research and Care. 2020.
- 380 7. Song IH, Zong J, Borland J, Jerva F, Wynne B, Zamek-Glisczynski MJ, et al. The effect of  
381 dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Acquir Immune Defic  
382 Syndr. 2016;
- 383 8. Mercadel CJ, Skelley JW, Kyle JA, Elmore LK. Dolutegravir: An integrase strand transfer  
384 inhibitor for the treatment of human immunodeficiency virus I in adults. J Pharm Technol. 2014;
- 385 9. Mooren FC, Krüger K, Völker K, Golf SW, Wadeuhl M, Kraus A. Oral magnesium  
386 supplementation reduces insulin resistance in non-diabetic subjects - a double-blind, placebo-  
387 controlled, randomized trial. Diabetes, Obesity and Metabolism. 2011.
- 388 10. Paolisso G, Scheen A, D'Onofrio F, Lefèbvre P. Magnesium and glucose homeostasis.  
389 Diabetologia. 1990.
- 390 11. Hailu W, Tesfaye T, Tadesse A. Hyperglycemia after dolutegravir-based antiretroviral therapy. Int

- 391 Med Case Rep J. 2021;
- 392 12. Marcovecchio ML. Complications of acute and chronic hyperglycemia. US Endocrinology. 2017.
- 393 13. Dobrica E, Gaman MA, Cozma MA, Gaman AM, Diaconu CC. MACROVASCULAR AND  
394 MICROVASCULAR COMPLICATIONS IN TYPE 2 DIABETES MELLITUS. J Hypertens.  
395 2019;
- 396 14. Ministry of Health. Consolidated Guidelines for Prevention and Treatment of HIV in Uganda |  
397 Ministry of Health Knowledge Management Portal. 2018;(February). Available from:  
398 [http://library.health.go.ug/publications/hiv-aids/consolidated-guidelines-prevention-and-treatment-](http://library.health.go.ug/publications/hiv-aids/consolidated-guidelines-prevention-and-treatment-hiv-uganda)  
399 [hiv-uganda](http://library.health.go.ug/publications/hiv-aids/consolidated-guidelines-prevention-and-treatment-hiv-uganda)
- 400 15. Sundberg F, Barnard K, Cato A, de Beaufort C, DiMeglio LA, Dooley G, et al. ISPAD Guidelines.  
401 Managing diabetes in preschool children. *Pediatr Diabetes*. 2017;
- 402 16. International Diabetes Federation. Diabetes Atlas, 2019. 9 th ed. Brussels, Belgium: IDF, 2019.  
403 2019.
- 404 17. Hirsch-Moverman Y, Howard AA, Mantell JE, Bongomin P, Wu Y, El-Sadr WM, et al. High  
405 prevalence of pre-diabetes among people living with HIV in a high TB burden setting.  
406 *International Journal of Tuberculosis and Lung Disease*. 2020.
- 407 18. Odenyo JA, Pharm B. Prevalence of Dolutegravir Associated Hyperglycemia and Its Covariates  
408 Among Persons Living With Hiv on Treatment At Kenyatta National Hospital. 2020;21(1):1–13.
- 409 19. Bahamdain FO. Effect of dolutegravir on plasma glucose among human immunodeficiency virus  
410 patients in a community health center setting. *Int J Community Med Public Heal*. 2022;
- 411 20. Namara D, Schwartz JI, Tsubira AK, McFarland W, Birungi C, Semitala FC, et al. The risk of  
412 hyperglycaemia associated with the use of dolutegravir among adults living with HIV in Kampala,  
413 Uganda: a case-control study. *Lancet Glob Heal*. 2022;10.
- 414 21. Fitch K V., Anderson EJ, Hubbard JL, Carpenter SJ, Waddell WR, Caliendo AM, et al. Effects of  
415 a lifestyle modification program in HIV-infected patients with the metabolic syndrome. *AIDS*.

- 416            2006;
- 417    22.    Robinson FP, Quinn LT, Rimmer JH. Effects of High-Intensity Endurance and Resistance  
418            Exercise on HIV Metabolic Abnormalities: A Pilot Study. *Biol Res Nurs*. 2007;
- 419    23.    Chawla SS, Kaur S, Bharti A, Garg R, Kaur M, Soin D, et al. Impact of health education on  
420            knowledge, attitude, practices and glycemc control in type 2 diabetes mellitus. *J Fam Med Prim  
421            Care*. 2019;
- 422    24.    C Miiro, GJ Imodia MM. Relationship between hyperglycemia and dolutegravir based HAART  
423            and the associated factors at Mbale regional referral hospital: A case-control study. 2022.
- 424    25.    Abera MA. Dolutegravir-Associated Hyperglycemia in People Living with Human Immune-  
425            Deciciency Virus: A Prospective Cohort Study. *Res Sq*. 2023;
- 426    26.    Mulindwa F, Castelnovo B, Brusselaers N, Bollinger R, Rhein J, Edrisa M, et al. Blood glucose  
427            trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on  
428            dolutegravir. *AIDS Res Ther*. 2023;
- 429